Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec;11 Suppl 3(Suppl 3):3-6.
doi: 10.1111/j.1477-2574.2009.00132.x.

Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery

J Enrique Domínguez-Muñoz  1
Affiliations

Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery

J Enrique Domínguez-Muñoz. HPB (Oxford). 2009 Dec.

Abstract

Exocrine pancreatic insufficiency (EPI) and resultant maldigestion occurs in up to 80% of patients following gastric, duodenal or pancreatic surgery. Accurate diagnosis is required to determine the appropriate intervention, but the conventional method of faecal fat quantification is time-consuming and not always readily available. The optimized (13)C-mixed triglyceride ((13)C-MTG) breath test is an accurate alternative post-surgery. Pancreatic enzyme replacement therapy (PERT) is indicated post-surgery in patients with clinically evident steatorrhoea, weight loss or maldigestion-related symptoms. Given its favourable safety profile, PERT is also appropriate in asymptomatic patients with high faecal fat excretion as such patients are at high risk for nutritional deficits. However, published data evaluating PERT in this setting are limited. Uncoated powder preparations may be preferred in cases of low gastric acidity and partial or total gastric resection. In clinical studies, enteric-coated microspheres were associated with greater weight gain after surgery vs. uncoated preparations. This was confirmed in a recent study using the (13)C-MTG breath test; fat absorption increased from <40% without therapy to almost 60% with enteric-coated minimicrospheres (40 000 lipase units/meal), with >60% of patients achieving normal breath test results (i.e. normal fat digestion) during PERT. A therapeutic algorithm for the treatment of EPI after surgery is also discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of control of post-prandial gastric and pancreatic function. CCK, cholecystokinin; CCK-RP, cholecystokinin-releasing peptide
Figure 3
Figure 3
Therapeutic algorithm for exocrine pancreatic insufficiency (EPI) in patients after gastroduodenal or pancreatic surgery. FFQ, faecal fat quantification; 13C-MTG, 13C-mixed triglyceride; U, units; PPI, proton pump inhibitor
Figure 2
Figure 2
Changes in body weight after duodenopancreatectomy. A mean increase in body weight of only 2 kg is obtained after 2 years of enzyme substitution therapy. A further mean body weight increase of 3 kg is obtained after just 6 months of therapy with pancreatic enzymes in the form of enteric-coated microspheres
See this image and copyright information in PMC

References

    1. Domínguez-Muñoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr Gastroenterol Rep. 2007;9:116–122. - PubMed
    1. Ewald N, Raspe A, Kaufmann C, Bretzel RG, Kloer HU, Hardt PD. Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations (FEC) in patients with diabetes mellitus. Eur J Med Res. 2009;14:118–122. - PMC - PubMed
    1. Leeds JS, Hopper AD, Hurlstone DP, Edwards SJ, McAlindon ME, Lobo AJ, et al. Is exocrine pancreatic insufficiency in adult coeliac disease a cause of persisting symptoms? Aliment Pharmacol Ther. 2007;25:265–271. - PubMed
    1. Seibold F, Scheurlen M, Müller A, Jenss H, Weber P. Impaired pancreatic function in patients with Crohn's disease with and without pancreatic autoantibodies. J Clin Gastroenterol. 1996;22:202–206. - PubMed
    1. Ito K. Duodenum preservation in pancreatic head resection to maintain pancreatic exocrine function (determined by pancreatic function diagnostant test and cholecystokinin secretion) J Hepatobiliary Pancreat Surg. 2005;12:123–128. - PubMed